Cardinal Health Reports Strong Q2 FY26 Results, Completes $2.4B Solaris Acquisition, and Announces Significant Share Repurchases

summarizeSummary

Cardinal Health reported robust second-quarter fiscal year 2026 financial results, driven by strong revenue and earnings growth, and detailed the completion of its $2.4 billion Solaris Health acquisition and substantial share repurchase activity.

check_boxKey Events

• Strong Q2 FY26 Financial Performance

  Reported 19% GAAP diluted EPS growth and 36% non-GAAP diluted EPS growth for the quarter, alongside 19% revenue growth, driven by pharmaceutical and specialty sales.

• Solaris Health Acquisition Completed

  Finalized the acquisition of Solaris Health, a urology MSO, for approximately $1.9 billion in cash and $500 million in equity, significantly expanding its MSO platform.

• Substantial Share Repurchases

  Deployed $750 million for common share repurchases during the six months ended December 31, 2025, with $2.0 billion remaining under the current program.

• New IRS Tax Contingency

  Disclosed a Notice of Proposed Adjustment from the IRS asserting an additional $160 million federal income tax liability plus interest related to a 2017 acquisition.

auto_awesomeAnalysis

The company demonstrated strong operational performance in Q2 FY26, with significant increases in both GAAP and non-GAAP revenue and EPS, largely fueled by branded and specialty pharmaceutical sales and contributions from recent acquisitions. The completion of the $2.4 billion Solaris Health acquisition further expands its multi-specialty MSO platform, a key strategic growth area. Additionally, the company deployed $750 million in share repurchases, signaling confidence and returning value to shareholders. While the filing also disclosed a new $160 million IRS tax contingency, the overall financial strength and strategic execution presented in this comprehensive quarterly report are likely to be viewed positively by investors.